These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 26101914)

  • 1. A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity.
    Song DG; Ye Q; Poussin M; Liu L; Figini M; Powell DJ
    Oncotarget; 2015 Aug; 6(25):21533-46. PubMed ID: 26101914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).
    Song DG; Ye Q; Carpenito C; Poussin M; Wang LP; Ji C; Figini M; June CH; Coukos G; Powell DJ
    Cancer Res; 2011 Jul; 71(13):4617-27. PubMed ID: 21546571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.
    Lanitis E; Poussin M; Hagemann IS; Coukos G; Sandaltzopoulos R; Scholler N; Powell DJ
    Mol Ther; 2012 Mar; 20(3):633-43. PubMed ID: 22127019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer.
    Ao X; Yang Y; Li W; Tan Y; Guo W; Ao L; He X; Wu X; Xia J; Xu X; Guo J
    J Immunother; 2019 Oct; 42(8):284-296. PubMed ID: 31261167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.
    Schutsky K; Song DG; Lynn R; Smith JB; Poussin M; Figini M; Zhao Y; Powell DJ
    Oncotarget; 2015 Oct; 6(30):28911-28. PubMed ID: 26359629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.
    Lanitis E; Poussin M; Klattenhoff AW; Song D; Sandaltzopoulos R; June CH; Powell DJ
    Cancer Immunol Res; 2013 Jul; 1(1):43-53. PubMed ID: 24409448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
    Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
    Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model.
    Ranoa DRE; Sharma P; Schane CP; Lewis AN; Valdez E; Marada VVVR; Hager MV; Montgomery W; Wolf SP; Schreiber K; Schreiber H; Bailey K; Fan TM; Hergenrother PJ; Roy EJ; Kranz DM
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells.
    Mirzaei HR; Jamali A; Jafarzadeh L; Masoumi E; Alishah K; Fallah Mehrjardi K; Emami SAH; Noorbakhsh F; Till BG; Hadjati J
    J Cell Physiol; 2019 Jun; 234(6):9207-9215. PubMed ID: 30362586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
    Li T; Wang J
    BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
    Mardiros A; Dos Santos C; McDonald T; Brown CE; Wang X; Budde LE; Hoffman L; Aguilar B; Chang WC; Bretzlaff W; Chang B; Jonnalagadda M; Starr R; Ostberg JR; Jensen MC; Bhatia R; Forman SJ
    Blood; 2013 Oct; 122(18):3138-48. PubMed ID: 24030378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
    Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
    J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity.
    Shabaneh TB; Stevens AR; Stull SM; Shimp KR; Seaton BW; Gad EA; Jaeger-Ruckstuhl CA; Simon S; Koehne AL; Price JP; Olson JM; Hoffstrom BG; Jellyman D; Riddell SR
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38325903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level.
    Song DG; Ye Q; Poussin M; Chacon JA; Figini M; Powell DJ
    J Hematol Oncol; 2016 Jul; 9(1):56. PubMed ID: 27439908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.
    Hudecek M; Lupo-Stanghellini MT; Kosasih PL; Sommermeyer D; Jensen MC; Rader C; Riddell SR
    Clin Cancer Res; 2013 Jun; 19(12):3153-64. PubMed ID: 23620405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
    Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
    Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.